Following upon French President François HOLLANDE’s State Visit in Seoul on the 4th of November 2015, our healthcare association was established by Business France and 5 major French healthcare companies : bioMérieux, Guerbet, Ipsen, Sanofi, and Servier.
Our History
-
2015
French President François HOLLANDE's State Visit in Korea
On the 4th of November 2015, during the State Visit of President François HOLLANDE in Seoul, has been launched the French Healthcare Korea association jointly led by Guerbet and Business France with the support of the other founding members: bioMérieux, Ipsen, Sanofi, and Servier.
-
2016
French Tech Days
On May 30th and 31st 2016, we participated in the French Tech Days, a top notch institutional forum that attracted no less than 300 Korean companies.
During this event, an eHealth symposium has been organized on the following thematic framework: « France and Korea: a bilateral cooperation to face today’s and tomorrow’s challenges ». -
2016
Dr. BARRE-SINOUSSI lecture, Nobel Price in Medicine, at Seoul National University Hospital
On the 24th of November 2016, in collaboration with Seoul National University Hospital, Dr. Françoise BARRE-SINOUSSI, Nobel Price 2008 in Medicine, gave a lecture about the following subject: « Toward novel HIV preventive & therapeutic stratégies ? ».
Over 200 students attended the lecture followed by a questions and answers session. -
2016
The French Health Care Day at Institut Pasteur Korea
On the 9th of December 2016, with Institut Pasteur Korea French Healthcare Korea association co-organized the French Health Care Day, final scientific event of the France-Korea Year 2015-2016. The symposium opened by M Fabien PENONE, French Ambassador gathered healthcare specialists from both France and Korea to discuss on the following thematic topics :
1. Health Care Associated infections Multi drug resistant organisms in healthcare facilities and community
2. Management of Hepatocellular carcinoma; Current Status and Future Perspectives
3. French-Korean health alliances for Tuberculosis-free Korea! -
2017
First plenary session
The French Healthcare Korea association held its first Plenary Meeting on Tuesday 24th October 2017 at the French Embassy. This event gathered over 30 companies involved in promoting healthcare between France and Korea.
M. SON FORGET, Member of French Parliament and head of French Korean Friendship group at the French Assembly, gave a speech where he insisted on the special links which exists between the two countries in healthcare sector and how positive the time sequence is to succeed in our projects.
The Secretary General reminds the main goals and priorities and presents the future projects of the association. -
2017
Meeting with Seoul National University Hospital Dean of Preventive Medicine
On the 30th of October, during the Visit of M SON FORGET, the Secretary General of our French Healthcare Korea association presented the joint diploma projects and got the support of the Dean.
It was the first step to enhance cooperation between Korean and French Universities. -
2018
Healthcare in South Korea
During the first semester, numerous events took place in order to present healthcare market :
• Business France Webinar 20th February
• French Patent and Trademark office's lectures 22nd March and 11th April
• Lecture by Nielsen Korea and French Tech Seoul 19th June
• Healthcare seminar in Paris 21st September -
2019
French officials visits
During the first semester, French Healthcare Korea was able to discuss with :
• Mr Mounir MAHJOUBI, Minister of State for the Digital Sector, 19th February
• Mrs Agnès PANNIER RUNACHER, Minister of State, attached to the Minister of Economy and Finance, 16th May
• Mr Cédric O, Minister of State for the Digital Sector, 4th November
Contact us at the Consulting office nearest to you or submit a business inquiry online.
Our Missions
We aim to:
- Promote scientific and academic exchanges between Korea and France in the healthcare area
- Contribute to the development of relations between the Korean and French scientific communities
- Promote the Korean health industry in France
- Strengthen the French presence in Korea
Contact us at the Consulting office nearest to you or submit a business inquiry online.
Founding Members
bioMérieux
Guerbet
Ipsen
Sanofi
Servier
Institutional Members
Business France
La French Tech Seoul
French Patent & Trademark Office
French Patent & Trademark Office (INPI) grants patents, trademarks and designs, while providing access to comprehensive information on industrial property and business. Our office assists innovators with administrative procedures, providing them with a full range of legal and technical documentation. This is easily accessible through databases of patents, trademarks and designs, as well as the National Register of Commerce and Companies, managed by INPI. To increase its support to businesses, the INPI is offering INPI Coaching, a new range of services to enable start-ups, SMEs and Mid-Caps companies to acquire and develop an intellectual property strategy that corresponds to their needs and environment.
The INPI Coaching team offers three customized services: IP BOOSTER, to initiate and review the company’s IP practices and assess its needs, IP PASS to consolidate and to encourage the company to implement the recommendations made in the IP BOOSTER and IP MASTER CLASS to get the company to include IP in its overall strategy.
Institut Pasteur Korea
Institut Pasteur Korea (IPK) is an international research institute focusing on global health issues with cutting-edge technologies in order to understand disease mechanisms and develop new treatments. By promoting multi-disciplinary projects, IPK is at the forefront of drug discovery and contributes to Korea’s future scientific resources through research, education and technological innovation.
The institute was established in April 2004 in collaboration with Institut Pasteur Paris and the Korea Institute of Science and Technology (KIST), with support from the Ministry of Science and ICT (MSIT) of Korea. IPK also receives support from the Gyeonggi Province. IPK is a private, non-profit foundation with four core missions of public interest – research, education, public health, and translation of biomedical discoveries to improve health via technology transfer and industrial partnerships.
IPK is a growth engine for Korea’s biomedical research industry, working successfully with biotech companies to develop multi-disciplinary R&D programs and translate fundamental discovery-based research into improvement of human, animal and environmental health.
Following Louis Pasteur’s belief, “Like the fruits in one tree, basic science and applied science are closely related”, IPK combines frontline biology, IT, and chemistry, with innovative cell-based drug discovery platforms that would identify novel molecular targets for potential new therapies to treat diseases. With world-class drug discovery capabilities and talented research teams recruited from all over the world, IPK scientists aim to uncover various physiological and pathological processes to develop new strategies for diagnosing, preventing and treating disease. IPK is currently focusing on global infectious diseases that represent today’s unmet medical needs such as tuberculosis, antibiotic resistance, hepatitis, influenza, cancer, dengue and neglected diseases, as well as preparing for emerging diseases that may impact future healthcare.
Private Members
AdEchoTech
AdhexPharma
Aguettant
Six areas of expertise for hospital settings with 60 proprietary products. Extensive experience and a range of products covering four main therapeutic areas : Emergency / Anesthesia / Resuscitation, Essential micronutrients, Neurology, Solutions.
Alpao
With more than 10 years of experience in adaptive optics, ALPAO’s deformable mirrors allow large stroke, fast deformation, high-resolution images and very good optical quality.
ALPAO is an international company with customers on four continents in over 20 countries. More than 90 percent of its turnover comes from exports.
Thanks to breakthrough technologies, ALPAO has introduced several products over the years, such as a low-speed deformable mirror (DM) its own wavefront sensor for closed loop operations in 2007, a hi-speed DM in 2008, new drive electronics in 2009, the DM97-08 dedicated to vision sciences application in 2013 and the DM 468 and 820 in 2015.
With a background in astronomy, ALPAO’s products are tailor-made for various applications, such as astronomy, ophthalmology, microscopy, wireless optical communication and laser applications.
Amplitude Laser Group
Anatoscope
AXA Direct
BioAxial SAS
a) designed for the study of cellular dynamics, thanks to its capacity to generate super resolved images (90 nm) with minimal cell illumination, maintaining cell integrity and preventing photobleaching;
b)a plug and play system requiring neither extensive, multi-skill staff training nor complex sample preparation;
c) 3 times more cost-effective than the few other comparable solutions;
d) soon with the ability to turn any fluorescence microscope into the latest generation SR system.
Bioserenity
Bioserenity customers are Hospitals and Pharmaceutical partners. The company has a 35 patents portfolio. The company investors are three of Paris largest private equity investors including BPI France. The company is profitable and its current stage of development is to ramp up production as well as geographical presence with help of partners.
The company current product line is designed to provide solutions that enable long measures done as point of care ar in ambulatory conditions. The current solution with CE and FDA approvals are targeting Neurology (Epilepsy, Trauma.), cardiology (Atrial Fibrillation, Ischemia,..). The company work in progress include similar solution for urology, maternity and Sleep disorder. Each solution include textile, Electronic and Smart device and Cloud software and can be used as a Holter, in telemetry and with Artificial intelligence based scientific support software.
Biotrial
Bioxis Pharmaceuticals
Bizmedtech
Cellprothera PTE LTD Singapore / Cellprothera SAS France
Dassault Systèmes
Direct Optic
DMS Imaging
Ecodas
EDAP TMS
EDAP TMS is the global leader in therapeutic ultrasound and present in the market for more than 35 years, EDAP TMS (NASDAQ: EDAP) develops, manufactures, promotes and distributes minimally-invasive medical devices for urology using ultrasound technology. EDAP TMS is actively operating worldwide via an extensive network of corporate offices, subsidiaries and distribution partners. By constantly investing in Research & Development, partnering with INSERM French public laboratory and internationally renowned medical research institutions, EDAP TMS has developed a strong valuable patent portfolio based on its innovative technologies.
HIFU (High Intensity Focused Ultrasound)
With its complete range of Robotic High Intensity Focused Ultrasound devices, Ablatherm® and Focal One®, EDAP TMS is the most innovative company in non-invasive treatment for Prostate Cancer. By combining the latest technologies in imaging and treatment modalities, EDAP TMS recently introduced the Focal One® device as the answer to current requirements for ideal focal therapy of prostate cancer and as a complement to the existing Ablatherm® HIFU.
ESWL (Extracorporeal ShockWave Lithotripsy)
As a pioneer and key player in the field of Extracorporeal ShockWave Lithotripsy, EDAP TMS introduced the first modular lithotripter. The latest generation of shockwave source (Electroconductive Technology) and stone localization (Visio-Track) are utilized exclusively by EDAP TMS in its Sonolith® range of ESWL systems (Sonolith® i-sys and Sonolith® i-move).
EDAP TMS Japan is the exclusive distributor for the following high-tech Medical Equipment companies: EOS Imaging (France), Rocamed (France), Laborie (Canada), Quanta Systems (Italy) and Sonesta (Sweden).
EUROFINS OPTIMED
Eurofins Optimed is the clinical competence center of the Eurofins Group, created in 1989.
We provide since 30 years integrated solutions for the global management of international clinical trials, to the pharma, biotech, and medical device industries.Focused on early clinical development, our experience of more than 1000 trials conducted since our creation establishes us as a reliable partner. We are able to provide you GCP services in any therapeutic field thank to our experienced team of experts and our large network of Key Opinion Leader.
Quality, Expertise & Flexibility are the key words of all our projects!
As every clinical project is specific, we offer tailor-made solutions among the following activities :
*Study document development: protocol, ICF, e-CRF, diaries, IMPD, etc.
*Regulatory support and submissions in Europe and in the US
*Clinical Investigations : healthy volunteers and ambulatory patients studies in our Clinical Pharmacology Unit (France – 60 beds) or Patients studies through our network of Investigators within Europe & the US
*Support services : feasibility studies (sites identification and qualification), project management, site coordination, monitoring
* Data collection and analysis : data management, statistics, e-CRF, medical writing, ePro
Our interconnected e-tools for global management, data management and global logistics provide a strong flexibility and interactivity with our clients, for the success of the trial.
Eveon
EVEON is the partner of pharmaceutical, biotech companies and medical device manufacturers for the development of automatic, secure and connected devices for preparation and administration of customers’ drugs
EVEON gets involved throughout the development cycle, in clinical or post-marketing phase. EVEON is an expert in the design of product, system and software engineering up to qualification, development, assemble regulatory approval and marketing
Our multidisciplinary skills allow us to support our clients and partners in the implementation of their tailor-made projects in accordance with our accreditation under ISO 13485 and IEC 62304 standards (medical device software).
EVEON works with a patient and practitioner-center approach to address health issues, with simple and intuitive solutions that improve therapeutic performance, patient compliance and home care.
Our innovative solutions meet specific requirements of new formulations, biologics, lyophilized or viscous drugs, as well as radiopharmaceutical products and cell therapies. Thanks to its unique technological platform, Intuit, EVEON is part of the digital blockchain and allow to facilitate and control the handling preparation (lyo dilution, liquid-liquid..) and administration (injection, infusion, spraying, nebulization..) of custromer’s drugs.
FACIL’iti
FACIL’iti was developed around the idea of offering a pool of settings adapting the display of a website, according to the motor, visual and cognitive needs in a will to make access to the web equal to all. Thus, each Internet user having difficulties on the internet, can benefit from a better accessibility to the sites by activating, according to his needs, one or more settings.
During the 5 years of R & D needed to create the solution, the technical team has partnered with disability associations in France to validate the needs of handinauts through user tests.
This is how many partnerships have been set up with leading players. After more than 18000 hours of design a patent was filed. Today FACIL’iti R & D continues to enrich the solution with new features and to meet ever more needs. FACIL’iti has been awarded numerous awards, has nearly 300,000 users and has just opened a subsidiary in Japan.
According to the World Health Organization, nearly a quarter of the world’s population suffers from a visual, motor or cognitive disorder (seniors, disability, transient disorders, …) to one degree or another, which prevents them at best from having an optimal web navigation, at worst to have access to the internet.
Aimed at people looking for browsing comfort on the internet, FACIL’iti offers many features to support many forms of visual, motor, cognitive and / or temporary needs.
For each type of adaptation the user will create a profile on his computer, tablet or smartphone (no data exchange so no GPRD problem) and the display on the screen of sites equipped with FACIL’iti s’ will automatically adapt to his need. Hundreds of adaptations are possible to have a customized navigation. This solution does not imply any modification or degradation of the existing site and therefore no resource mobilization for the site owner. FACIL’iti can also fit on an intranet.
Laboratoires Gilbert
Greentech SA
HalioDX
Immuno-oncology diagnostic transforms the way cancer patients are managed today.
The complexity of the immune response to tumors calls for intensifying and combining academic and industry efforts to better understand the biology of the immune response to cancers and provide validated assays for patients.
Thanks to the pioneering work of HalioDx co-founder Jerôme Galon and its INSERM team at the Centre de Recherche des Cordeliers in Paris, HalioDx is at the forefront of Immuno-oncology diagnostics with a range of tools and a rich pipeline of proprietary immuno-oncology diagnostic applications such as Immunoscore®.
As an expert in immune biomarkers, HalioDx goal is to play a leading role in partnering with academic and pharmaceutical industry to leverage the immune contexture concept and deliver practical routine diagnostic tools to significantly impact therapy prescription for the benefit of patients.
By precisely measuring the immune reaction in and around the tumor, HalioDx first tests already allow clinicians to determine the degree of severity of a patient’s disease and predict the response to treatment, regardless of the cancer stage or the molecular class.
We envision that the evaluation of the immune response to tumors will be the new diagnostic standard in Oncology :
*To guide existing treatment options, as the Immune contexture of tumors largely determines patients’ clinical outcomes.
*To guide the development of single and combined immunotherapies as clinical response is intimately dependent upon tumor immune microenvironment status.
HalioDx is able to provide today :
a) Immunoscore in localised colon cancer, stages I, II and III. New development and indications will soon be released.
b) Immunoscore IC in lung cancer.
c) Immunogram (R&D)
Healsy
Herdegen
Laboratoires INELDEA
Founded in 2003, LABORATOIRES INELDEA develops, manufactures and distributes innovative natural products in France and worldwide: health food supplements, natural cosmetics, organic products.
With formulas based on strong and natural scientific principles, we dedicate our knowledge in nutrition to offer global and preventive new therapeutic approach with adapted nutritional solution to preserve people health in their lifestyle:
- A multi-channels marketing expertise: pharmacy, parapharmacy, specialized and dietetic shops, physiotherapists, well-being and beauty centers, spas, mail order, e-commerces
- A broad portfolio of products (over 300 different references) with 30 to 35 innovations per year
- Certifications: ISO 22000-ECOCERT
A commitment for sustainable development and environment friendly process.
InvivoGen Limited
Invivox.com
Invivox enables:
* Physicians to find the training they need to acquire a new skill
* Medical Experts to organize and publish on a global platform their training sessions
* Medical Device manufacturers to list their trainings
* Hospital to get a new window of visibility for their training program
Kobridge Co. Ltd
Regulatory partner for medical devices manufacturers exporting to South Korea, license holder for South Korea.
FDA, MDSAP, CE markin, Japan PAL.. experts.
KOELIS SAS
Lyonbiopole
Mauna Kea Technologies
MD101 Consulting
Medicalps
Founded in 2000, MEDICALPS is a NPO and a cluster of companies in the field of healthcare technologies. It is located in Grenoble, in the heart of the French Alps, known as one of the most inventive cities in the world and a top-notch place to innovate in the high-tech industry.
MEDICALPS gathers over 100 members including leading edge startups, SMEs, global players, world-class research centres and universities.Although actively supported by local authorities, MEDICALPS is mainly governed by a community of entrepreneurs who aim to ensure the visibility, growth and international development of member companies.
With a unique emphasis on the healthcare technology sector, our objectives focus on :
- Gathering stakeholders and promoting the local ecosystem through communication tools and networking opportunities.
- Facilitating member operations by setting up workshops, presence at exhibitions and conventions and a soft landing programme in US in addition to other services.
- Structuring the local healthcare sector by developing shared undustrial resources.
Throughout the year, we organize events (workshop, training sessions…) to bring answers to operational and strategic needs of our members, with the aim to accelerate their development and growth.
Naos Korea Ltd
NGS Global
Orpea-clinea
Created in 1989 by Doctor Marian, the Group ORPEA-CLINEA has for vocation to welcome within its establishments of the people in loss of autonomy (physical or psychic) to provide medical care them essential in their well-being and to accompany them in the gestures of current life, in the respect for their dignity and for their individuality.
ORPEA-CLINEA so proposes a global offer of welcome, services and care for the dependent people, allowing a continuum of coverage, in average and long stays, whatever the age and the loss of autonomy :
*Residences seniors and nursing homes (EHPAD) under the name ORPEA
*Private hospitals of Care in a row and Rehabilitation (SSR) and private psychiatric hospitals, in France under the sign CLINEA
*In-home services, with agencies DOMIDOM and ADHAP service
Within 30 years, ORPEA-CLINEA became one of the European leaders of the global coverage of the Dependence, and refreshed of a network of 818 establishments (86 650 beds) distributed in 10 countries in Europe, in China and soon in Brazil. The Group makes a commitment to implement all the average human beings and the techniques necessary for the well-being of the patients and the residents and for the quality of exemplary coverage.
Four strategic axes guide our approach this way:
*Quality of the care and the hotel services
*In-service training of the teams
*Quality procedures and effective safety
*Search perms new solutions and approaches of coverage
Physiogenex
Pierre Fabre Dermo-Cosmetique
Pylote
By using exclusive manufacturing process to create 100% mineral protection, Pylote facilitates its clients’ ability to propose end-consumers with end-products, that are cleaner, greener and safer and respond favorably to the ever increasing myriad of regulatory, environmental and health pressures. Through a complete industrial offer and a licensed commercial model, we bring added value to its clients & partners, who are present in pharmaceutical, cosmetic, food and industrial markets, by proposing end consumers with greener, cleaner and safer products.
Pixyl
Septodont
Stago
Sterimed
Formerly Arjowiggins Healthcare, STERIMED Infection Control specializes in the supply of sterilization packaging solutions to hospitals, medical device manufacturers & pouch making industry. We provide our customers with a unique support in the field of:
a) wet laid non woven & polymer reinforced porous substrates,
b) cellulose, SMS & non woven sterilization wraps and
c) development of tailor-made solutions to their specific needs (output, biodegradability, seal & peel performance).
All products are manufactured in sites 100% dedicated to the healthcare industry on all their production tools, every day of the week, all year long. Today, 1 out of 4 medical devices in the world are packed with one of its packaging solution.
Supersonic Imagine
SuperSonic Imagine is a medical ultrasound imaging company based in Aix-en-Provence (France) that has developed a unique technology to image at UltraFast frame rate (up to 20,000Hz). This capability is the enabler to visualize a new parameter in tissue, namely tissue stiffness.The clinical focus of the company has originally been on early breast cancer detection improving the specificity of the diagnostic. More recently a new focus has been the liver with the non-invasive assessment of liver fibrosis as well as NASH/NAFLD.The UltraFast approach is key to the improvement of the Doppler function in greatly enhancing signal sensitivity, enabling the visualization of microvasculature in organs or lesions without the need to use contrast agents.The company is selling the product Aixplorer directly in France, USA and China. Aixplorer has received regulatory approval in more than 50 countries around the world. The Korean distributor for SuperSonic Imagine is Dongseo Medicare CO., Ltd.
Surgivio
Thuasne
Urgo
Veolia Korea
With around 1,840 employees, Veolia Korea delivers its unique technology and operation know-how on 59 sites, for industrial and municipal water and wastewater treatment, waste management and energy services.
In relation to the healthcare market, Veolia Korea affiliate ‘Hanbul Energy Management’ provides BES (Building Energy Services) to numerous hospitals in Korea. Veolia Water Technologies is also active locally with its certified equipment dedicated to the production of ultra-pure water for medical laboratory or industrial purposes.
Vetoquinol
VIGITECHNICS
TwinCruiser range products and its related PX07 disinfectant.
VitaDX International
VitalAire Korea Inc
Vygon
Wise Implants
It is free to exploit implants design all over the world on the medical and healthcare field.
Wise implants comes from the association of five skilled profiles : Philippe GUEDON, CEO and former head of development at MEDICEN, the Paris Biocluster; Madjid DJEMAÏ, CEO at Z3Dlab and expert on additive manufacturing; Jean-Jacques FOUCHET, VP Business Developer at Z3Dlab; Pr Jacques FAIN, maxilla-facial surgeon at AP-HP and Isabelle FOUCHET, former reporter and expert on PR.
Wise Implants business lies as well in Asia (from Korea), Europe (from France) and is to settle a subsidiary in the US.
YSLAB
Based in the West Coast of France, YSLAB incorporate world class expertise in Marine Biotechnology with innovative delivery systems to offer high quality OTC / OTX products based on marine active ingredients, with unique consumer benefits, sound scientific proof, regulatory approval and reliable manufacturing.
The biologic activity of active marine ingredients, their efficiency and tolerance are all tested in cooperation with best-in-class experts.
The laboratory is assisted by scientific and medical councils for product design and clinical testing within health protocol.
The company has focused its research to provide children and families efficient and safe health solutions from its marine Pharmacopea. The company activities range from design to manufacturing, regulatory and marketing aspects.
Z3DLAB SAS
Z3DLAB is a technology company specialized in additive manufacturing (AM) and advanced material. It has developed two new materials: A Titanium with Nano-Ceramic fused in AM process :
a/ ZTi-Powder for the industry and Medical coating -a world premiere-
b/ ZTi-Med for the medical industry
i. Non-Toxic
and ii. GPa close to the bone -elasticity-
Z3dlab through its advanced material can design Functional Gradient Material and through its expertise in AM is able to tailor mechanical and bio-compliance parts for medical as well as for the Aeronautic and Automobile industry. Z3DLAB has established with HS-HiTech a Korean a Joint Venture to established Z3DFAB a Digital AM production center in Korea to start first in the medical field.